An Open-Label Prospective Multi-Center Randomized Clinical Trial to Evaluate The Efficacy and Safety Of TheraSphere Followed by Durvalumab (Imfinzi ) With Tremelimumab Versus TheraSphere Alone For Hepatocellular Carcinoma (HCC)
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Hepatocellular Carcinoma
-
Age: Between 18 Year(s) - 100 Year(s)
-
Gender: Male or Female
-
Other Inclusion Criteria:
-
In order to participate in this trial the following criteria must be met:
- 1) Willingness and ability to participate in study intervention.
- 2) Diagnosis of localized breast cancer (stage 0-III).
- 3) Candidate for curative partial or whole breast or chest wall irradiation lumpectomy or mastectomy.
You may not be eligible for this study if the following are true:
-
-
You will not be able to participate in this trial if:
- 1) You are participating in an interventional clinical trial which involves topical application of an experimental agent to the radiation field.
- 2) You are a vulnerable subject.
- 3) Individuals who lack the capacity to consent.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.